Oncocyte CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
SCHEDULE 13G/A: AWM Investment Company Reports 9.99% Stake in Oncocyte Corp
AWM Investment Company, Inc. has filed an amended Schedule 13G, disclosing a 9.99% beneficial ownership stake in Oncocyte Corp as of March 31, 2025.
Bio-Rad Laboratories, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 9.66% of Oncocyte Corporation's common shares as of February 10, 2025.
AWM Investment Company, Inc. has filed an amended Schedule 13G, disclosing a 7.5% passive ownership stake in Oncocyte Corp. as of December 31, 2024.